Fennec Pharmaceuticals is a commercial-stage specialty pharma company built around a single product: PEDMARK (sodium thiosulfate injection), the only FDA- and EU-approved therapy to reduce the risk of cisplatin-induced hearing loss in pediatric patients with localized solid tumors. Cisplatin causes permanent hearing loss in an estimated 50–90% of pediatric patients, and PEDMARK is administered as a short IV infusion six hours after cisplatin dosing, a timing designed to let cisplatin complete its antitumor activity before PEDMARK neutralizes residual cisplatin in the cochlea. In the U.S., Fennec sells PEDMARK through a direct field force targeting oncologists, pharmacists, nurses, and audiologists at roughly 200 pediatric hospital centers and community oncology practices. PEDMARK is priced at $11,000 per vial, and management estimates every 100 incremental patients adds roughly $30M in net revenue. COGS are in the mid-single digits as a percentage of net sales, yielding high gross margins with significant operating leverage. Outside the U.S., Fennec has licensed PEDMARQSI to Norgine for commercialization in Europe, Australia, and New Zealand, receiving ~$43M upfront and eligible for up to ~$230M in additional milestones plus tiered royalties in the mid-teens to mid-twenties range. Fennec's primary near-term growth driver is the adolescent and young adult market in the U.S., which at an estimated 20,000 cisplatin-treated patients annually is roughly 10x larger than the pediatric market, supported by an NCCN 2A recommendation for patients aged 15–39.